Donepezil Tied to Risk for Overactive Bladder
THURSDAY, Jan. 13, 2022 -- There is an increased risk for overactive bladder (OAB) with the cholinesterase inhibitor (ChEI) donepezil versus rivastigmine, according to a study published online Dec. 2 in the Journal of the American Geriatrics...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Donepezil | Geriatrics | Overactive Bladder | Overactive Bladder Syndrome | Pharmaceuticals | Study